Jaguar Health JAGX Stock
Jaguar Health Price Chart
Jaguar Health JAGX Financial and Trading Overview
Jaguar Health stock price | 4.3 USD |
Previous Close | 0.7 USD |
Open | 0.67 USD |
Bid | 0 USD x 1100 |
Ask | 0 USD x 2900 |
Day's Range | 0.67 - 0.7 USD |
52 Week Range | 0.46 - 28.5 USD |
Volume | 322.92K USD |
Avg. Volume | 3.24M USD |
Market Cap | 13.36M USD |
Beta (5Y Monthly) | 1.822535 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -130.69 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6 USD |
JAGX Valuation Measures
Enterprise Value | 33.61M USD |
Trailing P/E | N/A |
Forward P/E | -0.11989708 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.181652 |
Price/Book (mrq) | 1.3494208 |
Enterprise Value/Revenue | 2.974 |
Enterprise Value/EBITDA | -1.104 |
Trading Information
Jaguar Health Stock Price History
Beta (5Y Monthly) | 1.822535 |
52-Week Change | -96.54% |
S&P500 52-Week Change | 20.43% |
52 Week High | 28.5 USD |
52 Week Low | 0.46 USD |
50-Day Moving Average | 0.64 USD |
200-Day Moving Average | 6.03 USD |
JAGX Share Statistics
Avg. Volume (3 month) | 3.24M USD |
Avg. Daily Volume (10-Days) | 385.23K USD |
Shares Outstanding | 19.11M |
Float | 17.17M |
Short Ratio | 0.12 |
% Held by Insiders | 2.05% |
% Held by Institutions | 0.55% |
Shares Short | 677.57K |
Short % of Float | 3.54% |
Short % of Shares Outstanding | 3.54% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:75 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -287.58% |
Gross Margin | 83.11% |
EBITDA Margin | -269.37% |
Management Effectiveness
Return on Assets (ttm) | -36.99% |
Return on Equity (ttm) | -540.65% |
Income Statement
Revenue (ttm) | 11.3M USD |
Revenue Per Share (ttm) | 0.8 USD |
Quarterly Revenue Growth (yoy) | -24.89% |
Gross Profit (ttm) | N/A |
EBITDA | -30447000 USD |
Net Income Avi to Common (ttm) | -41670000 USD |
Diluted EPS (ttm) | -14.99 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 14.37M USD |
Total Cash Per Share (mrq) | 0.75 USD |
Total Debt (mrq) | 34.3M USD |
Total Debt/Equity (mrq) | 447.72 USD |
Current Ratio (mrq) | 1.041 |
Book Value Per Share (mrq) | 0.518 |
Cash Flow Statement
Operating Cash Flow (ttm) | -35354000 USD |
Levered Free Cash Flow (ttm) | -16890000 USD |
Profile of Jaguar Health
Country | United States |
State | CA |
City | San Francisco |
Address | 200 Pine Street |
ZIP | 94104 |
Phone | 415 371 8300 |
Website | https://jaguar.health |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 60 |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.
Q&A For Jaguar Health Stock
What is a current JAGX stock price?
Jaguar Health JAGX stock price today per share is 4.3 USD.
How to purchase Jaguar Health stock?
You can buy JAGX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Jaguar Health?
The stock symbol or ticker of Jaguar Health is JAGX.
Which industry does the Jaguar Health company belong to?
The Jaguar Health industry is Biotechnology.
How many shares does Jaguar Health have in circulation?
The max supply of Jaguar Health shares is 656.09K.
What is Jaguar Health Price to Earnings Ratio (PE Ratio)?
Jaguar Health PE Ratio is now.
What was Jaguar Health earnings per share over the trailing 12 months (TTM)?
Jaguar Health EPS is -130.69 USD over the trailing 12 months.
Which sector does the Jaguar Health company belong to?
The Jaguar Health sector is Healthcare.
Jaguar Health JAGX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15250.5 USD — |
-2.16
|
1.78B USD — | 14784.03 USD — | 15263.41 USD — | — - | 1.78B USD — |
NASDAQ Capital Market Composite RCMP | 87.03 USD — |
-5.57
|
— — | 86.91 USD — | 88.47 USD — | — - | — — |
NASDAQ HealthCare IXHC | 834.97 USD — |
-4
|
— — | 828.4 USD — | 842.16 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19497.38 USD — |
+2.19
|
— — | 18095.83 USD — | 19679.81 USD — | — - | — — |
- {{ link.label }} {{link}}